(Q34274239)

English

Regorafenib for cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Regorafenib for cancer (English)

1 reference

Europe PubMed Central

1 August 2017

1 reference

ChEBI release 2020-05-28

author name string

Dirk Strumberg

1

1 reference

Europe PubMed Central

1 August 2017

Beate Schultheis

2

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

1 June 2012

1 reference

Europe PubMed Central

1 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

1 August 2017

21

1 reference

Europe PubMed Central

1 August 2017

879-889

1 reference

Europe PubMed Central

1 August 2017

6

1 reference

Europe PubMed Central

1 August 2017

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

MAP kinase signalling pathways in cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Management of hypertension in angiogenesis inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Renal effects of anti-angiogenesis therapy: update for the internist

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Experience with sorafenib and adverse event management.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.684752

21 January 2018

Identifiers

10.1517/13543784.2012.684752

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34274239&oldid=1981722002"